Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study
Arthritis Res Ther. 2024 12;26:197 doi 10.1186/s13075-024-03412-8
Baraliakos et al. assessed the long-term efficacy and safety of upadacitinib in patients with active ankylosing spondylitis who were refractory to biologic therapy. At week 104, the treatment sustained improvements in disease activity and functional outcomes with low rates of radiographic progression and no new safety signals.
This study focused on patients in the open-label extension of SELECT-AXIS 2, evaluating radiographic progression, safety, and clinical efficacy of upadacitinib through 2 years. 93% of patients showed no radiographic progression, and overall response rates were consistent regardless of prior biologic treatment failures.
Keywords:
